Science
Al-Ola Abdallah: BCMA Bispecifics in RRMM Raise New Questions About Fixed-Duration Therapy
Al-Ola Abdallah/X

Al-Ola Abdallah: BCMA Bispecifics in RRMM Raise New Questions About Fixed-Duration Therapy

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared on X:

“The apparent flattening of PFS curves beyond ~18 months with BCMA bispecifics in RRMM raises a question:

Could combinations enable fixed-duration therapy? Encouraging durability IMO.”

Al-Ola Abdallah: BCMA Bispecifics in RRMM Raise New Questions About Fixed-Duration Therapy

Title: Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals

Authors: Jordan Snyder, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Alma Habib, Hira Shaikh, Christopher Strouse, Omar Alkharabsheh, Anita Mazloom, Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Anas Zayad, Joseph McGuirk, Yun Kyoung Tiger, Mansi R. Shah, Al-Ola Abdallah

Read the full article.

You can also read:

Myeloma Paper of the Day, October 26th, Suggested by Robert Orlowski

Al-Ola Abdallah: BCMA Bispecifics in RRMM Raise New Questions About Fixed-Duration Therapy

Abdullah Mohammad Khan Al-Ola Abdallah Alma Habib Anas Zayad Anita Mazloom Barry Paul cancer Christopher Strouse Hira Shaikh Jordan Snyder Joseph McGuirk Mansi R. Shah Muhammad Umair Mushtaq Myeloma Nausheen Ahmed Omar Alkharabsheh OncoDaily Oncology Shebli Atrash Yun Kyoung Tiger Zahra Mahmoudjafari